-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-11X in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-11X in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-11X in Leiomyosarcoma Drug Details: TT-11X is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTX-080 in Metastatic Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TTX-080 in Metastatic Renal Cell Carcinoma Drug Details: TTX-080 is under development for the treatment...
-
Product Insights
Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RYZ-101 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RYZ-101 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RYZ-101 in Small-Cell Lung Cancer Drug Details: RYZ-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedatolisib in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedatolisib in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gedatolisib in Head And Neck Cancer Squamous Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RYZ-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RYZ-101 Drug Details RYZ-101 is under development for the treatment of gastroenteropancreatic neuroendocrine tumors...
-
Product Insights
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...